THROMBOSIS AND HAEMOSTASIS

Scope & Guideline

Bridging Research and Clinical Practice in Hemostasis

Introduction

Welcome to your portal for understanding THROMBOSIS AND HAEMOSTASIS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0340-6245
PublisherGEORG THIEME VERLAG KG
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1976 to 2024
AbbreviationTHROMB HAEMOSTASIS / Thromb. Haemost.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRUDIGERSTR 14, D-70469 STUTTGART, GERMANY

Aims and Scopes

The journal 'Thrombosis and Haemostasis' focuses on advancing the understanding of thrombosis and hemostasis through the publication of high-quality research. It encompasses a wide range of topics related to blood coagulation, platelet function, vascular biology, and the management of thrombotic disorders.
  1. Thrombosis and Hemostasis Mechanisms:
    The journal emphasizes research on the underlying biological mechanisms of thrombosis and hemostasis, exploring the molecular, cellular, and genetic factors that contribute to these processes.
  2. Clinical Outcomes and Management Strategies:
    A significant focus is placed on clinical studies that assess the effectiveness of various anticoagulant therapies, management strategies for patients with thrombotic disorders, and the implications of these treatments on patient outcomes.
  3. Innovative Therapeutic Approaches:
    The journal highlights studies that explore novel therapeutic approaches for managing thrombotic and bleeding disorders, including the development of new anticoagulants and antiplatelet agents.
  4. Risk Assessment and Predictive Modeling:
    Research on risk factors and predictive models for thrombotic events is a key area of interest, aiming to improve risk stratification and patient management.
  5. Translational Research:
    The journal publishes findings that bridge basic science and clinical practice, facilitating the translation of laboratory discoveries into therapeutic applications for patients with thrombotic disorders.
The field of thrombosis and hemostasis is evolving, and recent publications in 'Thrombosis and Haemostasis' reveal several emerging trends and themes reflecting current research priorities and advancements in the field.
  1. COVID-19 and Thrombosis:
    A significant increase in research focusing on the relationship between COVID-19 and thrombotic events highlights the pandemic's impact on thrombosis research, emphasizing the need for understanding coagulopathy in infected patients.
  2. Personalized Medicine in Anticoagulation:
    Emerging studies emphasize the importance of personalized approaches to anticoagulation therapy, including tailoring treatments based on genetic, phenotypic, and clinical characteristics of patients.
  3. Machine Learning and Predictive Analytics:
    The integration of machine learning techniques for predicting thrombotic events and optimizing treatment strategies is gaining traction, reflecting a broader trend towards data-driven decision-making in healthcare.
  4. Cancer-Associated Thrombosis:
    Research specifically addressing the complexities of thrombosis in cancer patients is increasingly prevalent, focusing on the unique risk factors and management strategies required for this population.
  5. Innovative Biomarkers:
    There is a growing emphasis on identifying and validating novel biomarkers for predicting thrombosis and bleeding risks, which may enhance risk stratification and personalized treatment approaches.

Declining or Waning

While 'Thrombosis and Haemostasis' continues to publish a diverse array of topics, certain themes appear to be declining in prominence over recent years. This shift may reflect changes in research priorities or advancements in understanding that render previous topics less central to current discourse.
  1. Traditional Anticoagulant Therapies:
    There is a noticeable reduction in studies focused solely on traditional anticoagulant therapies such as warfarin, as newer agents like direct oral anticoagulants (DOACs) gain prominence in research.
  2. Basic Science of Hemostasis:
    Research that solely focuses on the basic science of hemostasis without practical clinical applications appears to be less frequent, as the journal shifts towards more clinically relevant studies.
  3. Static Risk Factor Studies:
    Studies that merely catalog risk factors without integrating them into predictive models or clinical applications are becoming less common, reflecting a trend towards more dynamic and actionable research.
  4. Single-Center Studies:
    There appears to be a decline in the publication of single-center studies as multi-center and larger cohort studies become the norm, likely due to the increased need for robust data in diverse populations.
  5. Pharmacokinetics of Established Drugs:
    Research focusing on the pharmacokinetics of well-established anticoagulants without new insights or comparative analyses is becoming less frequent, as emphasis shifts to novel agents and their clinical implications.

Similar Journals

Hematology-American Society of Hematology Education Program

Advancing Hematology through Expert Education
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Transforming cardiovascular health through impactful discoveries.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1079-5642Frequency: 12 issues/year

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

Journal of Hematology

Empowering Research, Transforming Lives
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Leading the Way in Hematology Innovation
Publisher: ELSEVIER SCIENCE INCISSN: 1538-7933Frequency: 12 issues/year

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

THROMBOSIS RESEARCH

Unveiling the Complexities of Thrombosis
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0049-3848Frequency: 12 issues/year

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.

Lancet Haematology

Connecting researchers and clinicians for better patient outcomes.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

BLOOD COAGULATION & FIBRINOLYSIS

Pioneering Research in Hematology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0957-5235Frequency: 8 issues/year

BLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Fostering Global Insights in Blood Research
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

BLOOD

Shaping the Future of Hematological Discovery.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Thrombosis Journal

Bridging gaps in knowledge on thrombotic diseases.
Publisher: BMCISSN: 1477-9560Frequency: 1 issue/year

Thrombosis Journal is a pioneering open-access publication offering critical insights into the field of hematology, contributing significantly to the understanding of thrombotic diseases. Published by BMC since its inception in 2003, this journal stands out with its commitment to accessibility and dissemination of research, ensuring that valuable findings are readily available to the global scientific community. With an impressive Q2 ranking in the Hematology category as of 2023, the journal boasts a notable presence in the Scopus rankings, positioned at Rank #73/137 in its field. Researchers, healthcare professionals, and students can benefit from a rich array of articles that encompass clinical studies, reviews, and innovative methodologies, all aimed at advancing knowledge and fostering collaboration in the field. The journal is headquartered in the United Kingdom, and its open-access model has enabled a diversity of perspectives and research innovations to flourish, solidifying Thrombosis Journal as an essential resource for those dedicated to combating thrombotic disorders.